The UK Medicines and Healthcare products Regulatory Agency is mandating boxed warnings on antidepressant leaflets to highlight suicidal thoughts and persistent sexual dysfunction risks across all 28 licensed drugs. Prompted by patient concerns and a coroner's report following Thomas Kingston's death, the updates include credit card-sized patient cards and revised wording removing chemical imbalance references. Health officials stress that drug benefits outweigh risks and urge patients to consult doctors before altering treatments.
Updated warnings and materials for antidepressant leaflets
- ▪The UK Medicines and Healthcare products Regulatory Agency expects all future licensed antidepressants to incorporate updated safety warnings on suicidal thoughts and sexual dysfunction to ensure consistent communication across healthcare settings
- ▪The UK Medicines and Healthcare products Regulatory Agency announced updated safety warnings for all 28 authorised antidepressants, introducing boxed warnings on suicidal thoughts and behaviours in patient information leaflets
- ▪The MHRA said a credit card-sized patient card is expected to be included in or on antidepressant medicine boxes to reinforce safety messages and provide resource details
Changes to wording on chemical imbalance and sexual dysfunction
- ▪The MHRA said Antidepressant leaflet wording will be amended to remove references to a chemical imbalance and describe drug function in line with current clinical understanding
- ▪The MHRA said Leaflets for certain antidepressants such as SSRIs will incorporate the explicit term Post SSRI Sexual Dysfunction to explain the risk of persistent symptoms after treatment ends
Guidance for healthcare professionals on patient discussions
- ▪The Medicines and Healthcare products Regulatory Agency advised healthcare professionals to discuss suicidal risks when starting antidepressants, changing dosages, or conducting routine reviews
- ▪Healthcare professionals are advised to inform patients that some antidepressants carry a risk of sexual dysfunction that may continue after stopping the medication
Statements from MHRA chief safety officer
- ▪Medicines and Healthcare products Regulatory Agency chief safety officer Dr. Alison Cave urged patients not to stop taking antidepressants without first consulting their healthcare professional
- ▪The Medicines and Healthcare products Regulatory Agency chief safety officer Dr. Alison Cave stated that antidepressant benefits outweigh risks for the vast majority of patients under clinical supervision
Commission on Human Medicines review
- ▪The Commission on Human Medicines' expert working group on antidepressant risk minimisation drew on input from general practice, pharmacy, nursing, psychiatry, epidemiology, and patient support organisations
- ▪The Commission on Human Medicines review into antidepressant safety was initiated after patients and families raised concerns regarding the communication of suicidal thoughts and persistent sexual dysfunction risks
Coroner report on the death of Thomas Kingston
- ▪Thomas Kingston took his own life while suffering from adverse effects of recently prescribed SSRI medications sertraline and citalopram
- ▪The senior coroner for Gloucestershire who investigated Thomas Kingston's death questioned whether risk communication regarding suicide and guidance on switching SSRI medications was adequate when patients experience no benefit or suffer adverse effects
- ▪In January 2025, the senior coroner for Gloucestershire issued a prevention of future deaths report following the inquest into the death of Thomas Kingston
Story comments
Loading comments…